Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

AI Chatbot-Enabled ePRO Monitoring and Nurse-Led Self-Management for Early-Stage Cardiovascular-Kidney-Metabolic Syndrome

29 settembre 2026 aggiornato da: Pei-Shan, Tsai, Taipei Medical University

AI Chatbot-Enabled ePRO Monitoring and Nurse-Led Self-Management for Early-Stage Cardiovascular-Kidney-Metabolic Syndrome: A Randomized Controlled Trial

This randomized controlled trial will evaluate the effectiveness of an AI chatbot-enabled electronic patient-reported outcome (ePRO) monitoring and nurse-led self-management intervention for adults with early-stage cardiovascular-kidney-metabolic (CKM) syndrome. A total of 80 participants will be randomly assigned to either the intervention or control group and followed for 6 months. Participants in the intervention group will complete weekly ePRO assessments through an AI-enabled platform and receive individualized feedback, self-management support, and nurse-led clinical follow-up when indicated. Participants in the control group will receive usual care and complete weekly ePRO assessments through a non-AI platform without automated feedback or structured nurse-led support. Outcomes will be assessed at baseline, 3 months, and 6 months and will include patient-reported health outcomes, patient activation, health literacy, healthcare utilization, and changes in CKM syndrome stage.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This two-arm, parallel-group randomized controlled trial will evaluate the effectiveness of an AI chatbot-enabled electronic patient-reported outcome (ePRO) monitoring and nurse-led self-management intervention for adults with early-stage cardiovascular-kidney-metabolic (CKM) syndrome. A total of 80 adults aged 40 years or older with stage 1 or stage 2 CKM syndrome will be recruited from one tertiary hospital in Northern Taiwan and followed for 6 months. Participants will be randomly assigned in a 1:1 ratio using computer-generated permuted block randomization with randomly varying block sizes of 4 and 6 and allocation concealment.

Participants in the intervention group will receive usual outpatient care plus an AI chatbot-enabled ePRO monitoring and nurse-led self-management intervention. The AI-enabled platform will support weekly ePRO monitoring, individualized feedback, self-management support, and risk identification. Nurses will review clinically significant alerts and provide individualized support, care coordination, and clinical escalation when indicated.

Participants in the control group will receive usual outpatient care and complete weekly ePRO assessments through a non-AI platform without automated feedback, individualized recommendations, risk alerts, or nurse-led follow-up based on their weekly ePRO responses.

Primary outcomes include the seven PROMIS-29 domain-specific T-scores and the 0-10 Pain Intensity score. Secondary outcomes include patient activation, health literacy, healthcare utilization, and changes in CKM syndrome stage. Patient-reported health outcomes, patient activation, health literacy, and CKM syndrome stage will be assessed at baseline, 3 months, and 6 months, while healthcare utilization will be assessed prospectively over the 6-month follow-up period, with data collected at 3 and 6 months and updated through interim participant reports.

Tipo di studio

Interventistico

Iscrizione (Stimato)

80

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Pei-Shan Tsai, PhD in Nursing
  • Numero di telefono: 27709 +886 2 2736 1661
  • Email: ptsai@tmu.edu.tw

Luoghi di studio

    • No. 250號, Wuxing St, Xinyi District, Taipei City, 110
      • Taipei, No. 250號, Wuxing St, Xinyi District, Taipei City, 110, Taiwan
        • Taipei Medical University

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

40 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

***Inclusion Criteria***

  • Adults aged ≥40 years
  • Meet the criteria for stage 1 or stage 2 cardiovascular-kidney-metabolic (CKM) syndrome
  • Receive regular outpatient care at the study hospital
  • Able to communicate in Chinese
  • Able to provide written informed consent and complete the required study assessments
  • Have access to a smartphone or tablet compatible with the study ePRO platform

***Exclusion Criteria***

  • Meet the criteria for stage 3 or stage 4 CKM syndrome, including known subclinical cardiovascular disease, a stage 3 cardiovascular risk equivalent, or established clinical cardiovascular disease
  • Have kidney failure requiring chronic kidney replacement therapy
  • Have a terminal illness with a life expectancy of <6 months
  • Have cognitive impairment that, in the judgment of the treating physician or research team, precludes informed consent or meaningful participation in the intervention
  • Are currently participating in another interventional study that could substantially influence the study outcomes

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Terapia di supporto
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: AI Chatbot-Enabled ePRO Monitoring and Nurse-Led Self-Management

Participants will receive usual outpatient care plus a 6-month AI chatbot-enabled ePRO monitoring and nurse-led self-management program, including weekly ePRO assessments, individualized feedback, self-management support, risk alerts, and nurse-led follow-up when indicated.

Participants in the intervention group will receive a six-month nurse-led, AI chatbot-enabled symptom monitoring and self-management program integrating weekly ePRO assessments. The intervention begins with a structured nurse-led intake session including CKM assessment, symptom review, goal setting, and training on chatbot use. Participants complete weekly PROMIS-29 v2.1 assessments via a smartphone-based chatbot, which provides automated, rule-based feedback, self-management guidance, and motivational prompts. A risk-stratification algorithm generates alerts when symptom deterioration is detected. Nurses review alerts daily and provide follow-up via messaging, teleconsultation, or referral depending on severity, with same-day escalation for high-risk symptoms.

Altro: Control group

Participants will receive usual outpatient care and complete weekly ePRO assessments through a non-AI platform without automated feedback, individualized recommendations, risk alerts, or structured nurse-led support based on their weekly ePRO responses.

Usual care based on standard outpatient follow-up, without access to the AI chatbot or nurse-led coordination

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
PROMIS-29 v2.1 Domain-Specific T-Scores and Pain Intensity
Lasso di tempo: Baseline, 3 months, and 6 months

The PROMIS-29 v2.1 Traditional Chinese version will be used to assess seven health domains: Physical Function, Anxiety, Depression, Fatigue, Sleep Disturbance, Ability to Participate in Social Roles and Activities, and Pain Interference. Each domain contains four items and will be scored separately and converted to standardized T-scores with a reference-population mean of 50 and standard deviation of 10. Higher T-scores indicate greater symptom burden for Anxiety, Depression, Fatigue, Sleep Disturbance, and Pain Interference, whereas higher T-scores indicate better health for Physical Function and Ability to Participate in Social Roles and Activities. Pain Intensity will be assessed separately using a single 0-10 numeric rating scale, with higher scores indicating greater pain intensity.

Baseline, 3 months, and 6 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Patient Activation Measure-13 (PAM-13)
Lasso di tempo: Baseline, 3 months, and 6 months.

Patient activation will be assessed using the 13-item Patient Activation Measure (PAM-13), which evaluates individuals' knowledge, skills, and confidence in managing their health. Items are rated on a 5-point response scale, including a "not applicable" option. Raw scores are converted to a 0-100 scale, with higher scores indicating greater patient activation.

Baseline, 3 months, and 6 months.
Mandarin Multidimensional Health Literacy Questionnaire (MMHLQ)
Lasso di tempo: Baseline, 3 months, and 6 months.

Health literacy will be assessed using the 20-item Mandarin Multidimensional Health Literacy Questionnaire (MMHLQ), which covers five domains: obtaining, understanding, evaluating, and applying health information, as well as communication and interaction. Each item is rated on a 4-point scale from very difficult to very easy. Scores are transformed to a 0-50 scale, with higher scores indicating better health literacy. Scores are categorized as insufficient (0-25), limited (>25-33), sufficient (>33-42), and excellent (>42-50).

Baseline, 3 months, and 6 months.
Healthcare Utilization
Lasso di tempo: Enrollment to 3 months and 3 months to 6 months

Healthcare utilization will be assessed prospectively based on participant self-report of the number of emergency department visits and hospitalizations occurring during each follow-up interval. Participants will also be encouraged to report such events through the study platform between scheduled assessments.

Enrollment to 3 months and 3 months to 6 months
Change in CKM Syndrome Stage
Lasso di tempo: Baseline, 3 months, and 6 months

CKM syndrome stage will be assessed using available clinical and laboratory information and participant-reported updates. Changes from baseline will be categorized as progression to a more advanced CKM syndrome stage or improvement to a lower stage.

Baseline, 3 months, and 6 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 ottobre 2026

Completamento primario (Stimato)

31 luglio 2027

Completamento dello studio (Stimato)

31 luglio 2029

Date di iscrizione allo studio

Primo inviato

23 aprile 2026

Primo inviato che soddisfa i criteri di controllo qualità

5 maggio 2026

Primo Inserito (Effettivo)

11 maggio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

5 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

29 settembre 2026

Ultimo verificato

1 maggio 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • N202603080

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual participant data (IPD) will not be publicly shared due to ethical and privacy considerations. However, de-identified datasets may be made available to qualified researchers upon reasonable request after publication, subject to approval by the corresponding author and the Institutional Review Board (IRB) of Taipei Medical University. Data sharing will comply with institutional policies and applicable data protection regulations

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .